| Histone deacetylation in epigenetics: an attractive target for anticancer therapy A Mai, S Massa, D Rotili, I Cerbara, S Valente, R Pezzi, S Simeoni, ... Medicinal research reviews 25 (3), 261-309, 2005 | 424 | 2005 |
| Sirtuin functions and modulation: from chemistry to the clinic V Carafa, D Rotili, M Forgione, F Cuomo, E Serretiello, GS Hailu, E Jarho, ... Clinical epigenetics 8, 1-21, 2016 | 382 | 2016 |
| Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect E Lara, A Mai, V Calvanese, L Altucci, P Lopez-Nieva, ... Oncogene 28 (6), 781-791, 2009 | 308 | 2009 |
| SIRT5 regulation of ammonia-induced autophagy and mitophagy L Polletta, E Vernucci, I Carnevale, T Arcangeli, D Rotili, S Palmerio, ... Autophagy 11 (2), 253-270, 2015 | 282 | 2015 |
| Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue A Galmozzi, N Mitro, A Ferrari, E Gers, F Gilardi, C Godio, G Cermenati, ... diabetes 62 (3), 732-742, 2013 | 262 | 2013 |
| Targeting histone demethylases: a new avenue for the fight against cancer D Rotili, A Mai Genes & cancer 2 (6), 663-679, 2011 | 243 | 2011 |
| Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides A Mai, S Massa, R Pezzi, S Simeoni, D Rotili, A Nebbioso, ... Journal of medicinal chemistry 48 (9), 3344-3353, 2005 | 243 | 2005 |
| Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes A Nebbioso, F Manzo, M Miceli, M Conte, L Manente, A Baldi, A De Luca, ... EMBO reports 10 (7), 776-782, 2009 | 178 | 2009 |
| Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties A Mai, D Rotili, D Tarantino, P Ornaghi, F Tosi, C Vicidomini, G Sbardella, ... Journal of medicinal chemistry 49 (23), 6897-6907, 2006 | 162 | 2006 |
| Structural basis of sirtuin 6 activation by synthetic small molecules W You, D Rotili, TM Li, C Kambach, M Meleshin, M Schutkowski, KF Chua, ... Angewandte Chemie International Edition 56 (4), 1007-1011, 2017 | 156 | 2017 |
| Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities D Rotili, S Tomassi, M Conte, R Benedetti, M Tortorici, G Ciossani, ... Journal of medicinal chemistry 57 (1), 42-55, 2014 | 135 | 2014 |
| Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases G Sbardella, S Castellano, C Vicidomini, D Rotili, A Nebbioso, M Miceli, ... Bioorganic & medicinal chemistry letters 18 (9), 2788-2792, 2008 | 133 | 2008 |
| Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling B Illi, CD Russo, C Colussi, J Rosati, M Pallaoro, F Spallotta, D Rotili, ... Circulation research 102 (1), 51-58, 2008 | 133 | 2008 |
| " Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models … A Savarino, A Mai, S Norelli, S El Daker, S Valente, D Rotili, L Altucci, ... Retrovirology 6, 1-10, 2009 | 131 | 2009 |
| Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans A Mai, D Rotili, S Massa, G Brosch, G Simonetti, C Passariello, ... Bioorganic & Medicinal Chemistry Letters 17 (5), 1221-1225, 2007 | 118 | 2007 |
| Epigenetic polypharmacology: A new frontier for epi‐drug discovery D Tomaselli, A Lucidi, D Rotili, A Mai Medicinal research reviews 40 (1), 190-244, 2020 | 105 | 2020 |
| Development of 1, 2, 4-oxadiazoles as potent and selective inhibitors of the human deacetylase sirtuin 2: structure–activity relationship, X-ray crystal structure, and … S Moniot, M Forgione, A Lucidi, GS Hailu, A Nebbioso, V Carafa, F Baratta, ... Journal of medicinal chemistry 60 (6), 2344-2360, 2017 | 104 | 2017 |
| p300/CBP-associated factor selectively regulates the extinction of conditioned fear W Wei, CM Coelho, X Li, R Marek, S Yan, S Anderson, D Meyers, ... Journal of Neuroscience 32 (35), 11930-11941, 2012 | 104 | 2012 |
| Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells D Rotili, D Tarantino, A Nebbioso, C Paolini, C Huidobro, E Lara, P Mellini, ... Journal of medicinal chemistry 55 (24), 10937-10947, 2012 | 102 | 2012 |
| Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases A Mai, D Rotili, D Tarantino, A Nebbioso, S Castellano, G Sbardella, ... Bioorganic & medicinal chemistry letters 19 (4), 1132-1135, 2009 | 100 | 2009 |
Antonello MaiProfessore di Chimica Farmaceutica, Sapienza Università di RomaVerified email at uniroma1.it
